Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.21.1
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Nov. 04, 2020
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]                  
Royalties payments $ 20,000,000   $ 8,000,000            
Due to licensor current     $ 8,000,000     $ 32,934,000   $ 31,515,000  
License to be paid   $ 8,000,000              
Interest payable                 $ 1,000,000
Debt instrument, maturity date     Apr. 01, 2020            
License termination date   May 02, 2020              
Non-cash licensed technology impairment charge           $ 32,916,000    
Amortization of intangible assets           29,000 $ 1,300,000    
Abeona Therapeutics LLC [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
Finite-lived intangible asset, useful life         20 years        
RDEB Product [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
Debt instrument, periodic payment, principal           28,000,000      
Debt instrument accrued interest           4,900,000      
Original License Agreement [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
License to be paid                 10,000,000
Eb Agreement [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
License to be paid                 3,000,000
Eb Agreement [Member] | Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1                  
Indefinite-lived Intangible Assets [Line Items]                  
License to be paid                 $ 8,000,000
REGENXBIO [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
Due remains value           $ 28,000,000      
Licensing Agreements [Member] | REGENXBIO [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
Royalty fees       $ 180,000,000          
Royalties payments $ 20,000,000     20,000,000          
Payment on execution of contracts       10,000,000          
Due to licensor current       10,000,000          
Milestone payment       $ 60,000,000          
Finite-lived intangible asset, useful life       8 years          
Loss contingency accrual               8,000,000  
Payments for legal settlements               $ 20,000,000  
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]                  
Indefinite-lived Intangible Assets [Line Items]                  
Annual fees       $ 100,000,000